GETTING MY TRACLEER TO WORK

6 The phosphodiesterase-5 inhibitor sildenafil is licensed for PAH in FC I–IV from the United states and FC II–III in Europe. Endothelin receptor antagonists (ERAs) which includes bosentan, sitaxentan and ambrisentan are oral therapies certified for use in PAH. As no oral agent has shown superiority there stays debate as to which need to be uti